NASDAQ:TARS Tarsus Pharmaceuticals (TARS) Stock Price, News & Analysis → [FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks (From Crypto 101 Media) (Ad) Free TARS Stock Alerts $38.58 +0.08 (+0.21%) (As of 05/16/2024 ET) Add Compare Share Share Today's Range$37.65▼$39.1050-Day Range$29.43▼$38.5852-Week Range$12.57▼$42.50Volume357,017 shsAverage Volume714,313 shsMarket Capitalization$1.46 billionP/E RatioN/ADividend YieldN/APrice Target$50.38 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Tarsus Pharmaceuticals alerts: Email Address Tarsus Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.88 Rating ScoreUpside/Downside30.6% Upside$50.38 Price TargetShort InterestBearish20.27% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.81Based on 23 Articles This WeekInsider TradingSelling Shares$749,578 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.03) to ($2.22) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.52 out of 5 starsMedical Sector281st out of 929 stocksBiological Products, Except Diagnostic Industry36th out of 155 stocks 4.4 Analyst's Opinion Consensus RatingTarsus Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageTarsus Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Tarsus Pharmaceuticals' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted20.27% of the outstanding shares of Tarsus Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverTarsus Pharmaceuticals has a short interest ratio ("days to cover") of 10.7, which indicates bearish sentiment.Change versus previous monthShort interest in Tarsus Pharmaceuticals has recently decreased by 3.04%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldTarsus Pharmaceuticals does not currently pay a dividend.Dividend GrowthTarsus Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TARS. Previous Next 3.8 News and Social Media Coverage News SentimentTarsus Pharmaceuticals has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 23 news articles for Tarsus Pharmaceuticals this week, compared to 3 articles on an average week.Search Interest10 people have searched for TARS on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.MarketBeat Follows5 people have added Tarsus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Tarsus Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $749,578.00 in company stock.Percentage Held by Insiders11.54% of the stock of Tarsus Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions90.01% of the stock of Tarsus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Tarsus Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Tarsus Pharmaceuticals are expected to grow in the coming year, from ($4.03) to ($2.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tarsus Pharmaceuticals is -8.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tarsus Pharmaceuticals is -8.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTarsus Pharmaceuticals has a P/B Ratio of 5.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Tarsus Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 Media[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Are you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealthy beyond your wildest dreams. You see, while Bitcoin and Ethereum steal all the headlines… It’s often the cryptos flying under the radar that turn small stakes into life-changing windfalls. Claim your free seat by clicking here now. About Tarsus Pharmaceuticals Stock (NASDAQ:TARS)Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.Read More TARS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TARS Stock News HeadlinesMay 15 at 6:32 AM | americanbankingnews.comHC Wainwright Comments on Tarsus Pharmaceuticals, Inc.'s Q2 2024 Earnings (NASDAQ:TARS)May 15 at 4:32 AM | americanbankingnews.comTarsus Pharmaceuticals (NASDAQ:TARS) Given New $61.00 Price Target at HC WainwrightMay 13 at 2:26 AM | americanbankingnews.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Average Rating of "Moderate Buy" from BrokeragesMay 13 at 1:14 AM | americanbankingnews.comWilliam Blair Comments on Tarsus Pharmaceuticals, Inc.'s Q2 2024 Earnings (NASDAQ:TARS)May 13 at 1:14 AM | americanbankingnews.comTarsus Pharmaceuticals, Inc. to Post Q2 2024 Earnings of ($1.10) Per Share, Lifesci Capital Forecasts (NASDAQ:TARS)May 12, 2024 | finance.yahoo.comEarnings Update: Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Just Reported And Analysts Are Boosting Their EstimatesMay 12, 2024 | americanbankingnews.comBarclays Increases Tarsus Pharmaceuticals (NASDAQ:TARS) Price Target to $60.00May 12, 2024 | americanbankingnews.comOppenheimer Raises Tarsus Pharmaceuticals (NASDAQ:TARS) Price Target to $61.00May 11, 2024 | americanbankingnews.comTarsus Pharmaceuticals (NASDAQ:TARS) Trading 5.8% Higher After Analyst UpgradeMay 10, 2024 | finance.yahoo.comTarsus Pharmaceuticals First Quarter 2024 Earnings: Beats ExpectationsMay 9, 2024 | markets.businessinsider.comAnalyst Ratings For Tarsus PharmaceuticalsMay 9, 2024 | globenewswire.comTarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare ConferenceMay 9, 2024 | finanznachrichten.deTarsus Pharmaceuticals, Inc: Tarsus Reports First Quarter 2024 Financial Results and Recent Business AchievementsMay 9, 2024 | msn.comTarsus Pharmaceuticals GAAP EPS of -$1.01 beats by $0.18, revenue of $27.61M beats by $9.71MMay 9, 2024 | finance.yahoo.comTarsus Pharmaceuticals Inc (TARS) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth ...May 8, 2024 | investorplace.comTARS Stock Earnings: Tarsus Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024May 8, 2024 | globenewswire.comTarsus Reports First Quarter 2024 Financial Results and Recent Business AchievementsMay 7, 2024 | markets.businessinsider.comTarsus Pharmaceuticals earnings: here's what Wall Street expectsMay 1, 2024 | globenewswire.comTarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024May 1, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Legend Biotech (LEGN), Organon (OGN) and Exelixis (EXEL)April 28, 2024 | latimes.comMaáza MartinApril 25, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Amneal Pharmaceuticals (AMRX) and Community Health (CYH)April 24, 2024 | lse.co.ukBioPharma Credit to loan USD100 million to Tarsus PharmaceuticalsApril 24, 2024 | markets.businessinsider.comBuy Rating Affirmed for Tarsus Pharmaceuticals Amidst Strategic Debt Refinancing and Strong Financial OutlookApril 23, 2024 | globenewswire.comTarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from PharmakonSee More Headlines Receive TARS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tarsus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today5/16/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:TARS CUSIPN/A CIK1819790 Webwww.tarsusrx.com Phone949-409-9820FaxN/AEmployees244Year FoundedN/APrice Target and Rating Average Stock Price Target$50.38 High Stock Price Target$61.00 Low Stock Price Target$30.00 Potential Upside/Downside+30.6%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($4.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-135,890,000.00 Net MarginsN/A Pretax Margin-348.22% Return on Equity-71.12% Return on Assets-55.30% Debt Debt-to-Equity Ratio0.11 Current Ratio8.01 Quick Ratio7.92 Sales & Book Value Annual Sales$42.56 million Price / Sales34.25 Cash FlowN/A Price / Cash FlowN/A Book Value$7.28 per share Price / Book5.30Miscellaneous Outstanding Shares37,782,000Free Float33,422,000Market Cap$1.46 billion OptionableOptionable Beta1.10 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Bobak R. Azamian M.D.Co-Founder, President, CEO & ChairmanDr. Bryan Wahl J.D. (Age 46)M.D., General Counsel & Corporate Secretary Comp: $619.09kDr. Elizabeth Yeu Lin M.D. (Age 46)Chief Medical Advisor & Director Comp: $286kMr. Jeffrey S. Farrow (Age 62)CFO & Chief Strategy Officer Dr. Seshadri Neervannan Ph.D. (Age 56)Chief Operating Officer Comp: $486.67kMr. David NakasoneHead of Investor RelationsMs. Adrienne KempSenior Director of Corporate CommunicationsMr. Matthew Rossen M.B.A. (Age 46)Vice President of Marketing Mr. Scott YoumansVice President of SalesMs. Dianne C. Whitfield M.S.W. (Age 47)Chief Human Resources Officer Comp: $578.9kMore ExecutivesKey CompetitorsVir BiotechnologyNASDAQ:VIRNeumora TherapeuticsNASDAQ:NMRA4D Molecular TherapeuticsNASDAQ:FDMTCullinan OncologyNASDAQ:CGEMScholar RockNASDAQ:SRRKView All CompetitorsInsiders & InstitutionsJanus Henderson Group PLCBought 8,596 shares on 5/16/2024Ownership: 0.023%Price T Rowe Associates Inc. MDBought 347,683 shares on 5/15/2024Ownership: 0.920%Healthcare of Ontario Pension Plan Trust FundBought 824,000 shares on 5/14/2024Ownership: 2.377%StemPoint Capital LPBought 50,000 shares on 5/14/2024Ownership: 0.000%EntryPoint Capital LLCSold 2,082 shares on 5/14/2024Ownership: 0.003%View All Insider TransactionsView All Institutional Transactions TARS Stock Analysis - Frequently Asked Questions Should I buy or sell Tarsus Pharmaceuticals stock right now? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tarsus Pharmaceuticals in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" TARS shares. View TARS analyst ratings or view top-rated stocks. What is Tarsus Pharmaceuticals' stock price target for 2024? 8 brokerages have issued 1 year price targets for Tarsus Pharmaceuticals' shares. Their TARS share price targets range from $30.00 to $61.00. On average, they anticipate the company's stock price to reach $50.38 in the next year. This suggests a possible upside of 30.6% from the stock's current price. View analysts price targets for TARS or view top-rated stocks among Wall Street analysts. How have TARS shares performed in 2024? Tarsus Pharmaceuticals' stock was trading at $20.25 at the beginning of 2024. Since then, TARS shares have increased by 90.5% and is now trading at $38.58. View the best growth stocks for 2024 here. When is Tarsus Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our TARS earnings forecast. How were Tarsus Pharmaceuticals' earnings last quarter? Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) issued its earnings results on Tuesday, February, 27th. The company reported ($1.31) EPS for the quarter, beating analysts' consensus estimates of ($1.37) by $0.06. The company had revenue of $13.08 million for the quarter, compared to the consensus estimate of $4.63 million. During the same quarter in the previous year, the firm earned ($0.49) earnings per share. What ETFs hold Tarsus Pharmaceuticals' stock? ETFs with the largest weight of Tarsus Pharmaceuticals (NASDAQ:TARS) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), ALPS Medical Breakthroughs ETF (SBIO) and iShares U.S. Pharmaceuticals ETF (IHE).iShares Micro-Cap ETF (IWC). When did Tarsus Pharmaceuticals IPO? Tarsus Pharmaceuticals (TARS) raised $80 million in an IPO on Friday, October 16th 2020. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. BofA Securities, Jefferies and Raymond James acted as the underwriters for the IPO and LifeSci Capital and Ladenburg Thalmann were co-managers. Who are Tarsus Pharmaceuticals' major shareholders? Tarsus Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (4.83%), Jennison Associates LLC (3.52%), Healthcare of Ontario Pension Plan Trust Fund (2.38%), Vivo Capital LLC (1.65%), Price T Rowe Associates Inc. MD (0.92%) and Allspring Global Investments Holdings LLC (0.56%). Insiders that own company stock include Andrew D Goldberg, Aziz Mottiwala, Bobak R Azamian, Bobak R Azamian, Bryan Wahl, Dianne C Whitfield, Elizabeth Yeu Lin, Jose M Trevejo, Leonard M Greenstein, Mark J Holdbrook, Michael Ackermann, Seshadri Neervannan and Vivo Capital Ix, Llc. View institutional ownership trends. How do I buy shares of Tarsus Pharmaceuticals? Shares of TARS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TARS) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersThe 1,000X Crypto PlaybookTrue Market InsidersGold Set to EXPLODE!Gold Safe ExchangeCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlaceWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaMost important medical advance in 100 yearsThe Oxford ClubBill Clinton Backing Biden Replacement???The Freeport SocietyCharles Payne Demystifies OptionsUnstoppable Prosperity Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tarsus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.